1. Home
  2. HSPO vs SLS Comparison

HSPO vs SLS Comparison

Compare HSPO & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HSPO
  • SLS
  • Stock Information
  • Founded
  • HSPO 2014
  • SLS 2012
  • Country
  • HSPO United States
  • SLS United States
  • Employees
  • HSPO N/A
  • SLS N/A
  • Industry
  • HSPO Blank Checks
  • SLS Biotechnology: Pharmaceutical Preparations
  • Sector
  • HSPO Finance
  • SLS Health Care
  • Exchange
  • HSPO Nasdaq
  • SLS Nasdaq
  • Market Cap
  • HSPO 92.0M
  • SLS 89.6M
  • IPO Year
  • HSPO 2022
  • SLS N/A
  • Fundamental
  • Price
  • HSPO $11.80
  • SLS $1.07
  • Analyst Decision
  • HSPO
  • SLS
  • Analyst Count
  • HSPO 0
  • SLS 0
  • Target Price
  • HSPO N/A
  • SLS N/A
  • AVG Volume (30 Days)
  • HSPO 1.4K
  • SLS 864.9K
  • Earning Date
  • HSPO 01-01-0001
  • SLS 03-20-2025
  • Dividend Yield
  • HSPO N/A
  • SLS N/A
  • EPS Growth
  • HSPO 2.63
  • SLS N/A
  • EPS
  • HSPO 0.91
  • SLS N/A
  • Revenue
  • HSPO N/A
  • SLS N/A
  • Revenue This Year
  • HSPO N/A
  • SLS N/A
  • Revenue Next Year
  • HSPO N/A
  • SLS N/A
  • P/E Ratio
  • HSPO $12.82
  • SLS N/A
  • Revenue Growth
  • HSPO N/A
  • SLS N/A
  • 52 Week Low
  • HSPO $10.87
  • SLS $0.77
  • 52 Week High
  • HSPO $12.41
  • SLS $1.84
  • Technical
  • Relative Strength Index (RSI)
  • HSPO 52.89
  • SLS 41.82
  • Support Level
  • HSPO $11.61
  • SLS $1.13
  • Resistance Level
  • HSPO $11.75
  • SLS $1.25
  • Average True Range (ATR)
  • HSPO 0.00
  • SLS 0.07
  • MACD
  • HSPO 0.00
  • SLS -0.00
  • Stochastic Oscillator
  • HSPO 50.00
  • SLS 19.05

About HSPO Horizon Space Acquisition I Corp.

Horizon Space Acquisition I Corp is a blank check company.

About SLS SELLAS Life Sciences Group Inc.

SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

Share on Social Networks: